Island Pharmaceuticals Limited: Granted Ethics Approval for ISLA-101 Study

Island Pharmaceuticals Ltd (ASX: ILA) in Australia has obtained significant approval from the Human Research Ethics Committee (HREC) to initiate the Single Ascending Dose study for ISLA-101. This novel study involves the repurposing of ISLA-101, a potential drug aimed at preventing and treating diseases transmitted by mosquitoes, particularly dengue. In this investigation, three different sets of healthy participants will receive increasing doses of ISLA-101 to establish safe and effective blood concentrations against the dengue virus.

The trial, set to take place at Scientia Clinical Research's trial facilities in Sydney, with support from Beyond Drug Development as the Contract Research Organization, is geared to commence immediate patient screening and dosing. Anticipated results are expected to be unveiled in early 2024. These findings are crucial, as they will serve as a guide for refining protocols for Island's forthcoming Phase 2a PEACH clinical trial, marking a significant step forward in the development of treatments for mosquito-borne diseases.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com